\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes Horizon Europe Digital Europe Horizon 2020Cascade funding, also known as Financial Support to Third Parties (FSTP), is a mechanism of the European Commission to distribute public funds in order to assist startups, scale-ups, SMEs and/or mid-caps in the uptake or development of innovation.
FSTP is a SME-friendly application scheme which allows that some EU-funded projects may issue, in turn, open calls for further funding. Currently, only the Horizon and Digital programmes may foresee the use of this feature.
All registered cascade funding calls are now available on the Funding & Tenders Portal: Search Funding & Tenders (europa.eu)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
